92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort
Publication
, Conference
Masuishi, T; Strickler, JH; Machiels, J-P; Hong, DS; Greil, R; Chan, E; Hippenmeyer, J; Saportas, Y; Cardona, P; Xia, C; Kuboki, Y
Published in: Annals of Oncology
November 2023
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
November 2023
Volume
34
Start / End Page
S1505 / S1505
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Masuishi, T., Strickler, J. H., Machiels, J.-P., Hong, D. S., Greil, R., Chan, E., … Kuboki, Y. (2023). 92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort. In Annals of Oncology (Vol. 34, pp. S1505–S1505). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.10.227
Masuishi, T., J. H. Strickler, J. -. P. Machiels, D. S. Hong, R. Greil, E. Chan, J. Hippenmeyer, et al. “92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort.” In Annals of Oncology, 34:S1505–S1505. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.10.227.
Masuishi T, Strickler JH, Machiels J-P, Hong DS, Greil R, Chan E, et al. 92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort. In: Annals of Oncology. Elsevier BV; 2023. p. S1505–S1505.
Masuishi, T., et al. “92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S1505–S1505. Crossref, doi:10.1016/j.annonc.2023.10.227.
Masuishi T, Strickler JH, Machiels J-P, Hong DS, Greil R, Chan E, Hippenmeyer J, Saportas Y, Cardona P, Xia C, Kuboki Y. 92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort. Annals of Oncology. Elsevier BV; 2023. p. S1505–S1505.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
November 2023
Volume
34
Start / End Page
S1505 / S1505
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis